BMP Signaling Luciferase Reporter Cell Lines
Introduction
The Bone Morphogenetic Protein signaling pathway (BMP signaling pathway) plays a critical role in embryonic development, organogenesis, and adult tissue homeostasis. Precise regulation of BMP signaling is essential for normal biological function.
Dysregulation of the BMP pathway has been strongly linked to a wide range of developmental disorders, cancer, and other human diseases affecting multiple organ systems. As a result, accurate and sensitive monitoring of BMP signaling activity is crucial for basic research, pathway analysis, and drug discovery applications.
To accelerate research on the BMP signaling pathway, Signosis has developed BMP/SMAD1/5/8 luciferase reporter in multiple human cell lines, including HEK293, HepG2, and A549.
Each stable cell line is transfected with the pTA-BMP luciferase reporter vector, containing four tandem repeats of SMAD1/5/8 response elements upstream of a minimal promoter driving firefly luciferase expression. This configuration ensures high sensitivity, low background, and robust signal output.
To further enhance signaling responsiveness, Signosis offers BMP reporter cell lines engineered to overexpress key BMP receptors, including ALK1 (ACVRL1) and BMPR2. Incorporating these receptors lowers basal background and produces significantly increased ligand‑induced activation compared with the standard reporter lines. This upgrade provides greater sensitivity, improved signal‑to‑noise, and more consistent BMP pathway readouts, making it ideal for high‑performance screening and mechanistic studies.
Principle
The Bone Morphogenetic Protein (BMP) signaling pathway is activated when BMP ligands, such as BMP9 or BMP10, bind to heteromeric receptor complexes consisting of type I and type II serine/threonine kinase receptors.
In this process, the type II receptor -- BMPR2 first binds the ligand and subsequently phosphorylates the type I receptor -- ALK1.
Activated ALK1 then phosphorylates the receptor-regulated SMAD proteins (SMAD1/5/8), which form a complex with the common mediator SMAD4.
This SMAD complex translocates into the nucleus, where it regulates the transcription of BMP-responsive genes involved in vascular homeostasis, cell proliferation, and differentiation.
Firefly Luciferase Reporter Stable Cell Lines
Signosis' cell line for monitoring NRF2 binding and activation using the standard Firefly Luciferase as the reporter.
Secreted Luciferase Reporter Stable Cell Lines
Secreted Luciferase Reporters Stable Cell Lines that offer many unique advantages over the standard Firefly Luciferase reporter. Secreted Luciferases allow for noninvasive, real-time monitoring of gene activation and long-term continuous studies on he same cell population, all while skipping the cell lysis step which will streamline your experimental procedures.
Name | SKU | Price (USD$) |
|---|---|---|
SMAD/BMP Secreted Luciferase Reporter HEK293 Stable Cell Line (2 vials) | SL-4051 | $3,870.00 |
Don't see a particular cell line of interest?
Applications
Drug Screening and Toxicology
Signosis’ BMP/SMAD1/5/8 luciferase reporter cell line offers a powerful tool for drug screening and toxicological assessments, specifically for compounds that modulate BMP signaling. BMPs, including BMP2, BMP4, BMP7, BMP9, and BMP10, are critical regulators of various cellular processes such as differentiation, tissue repair, and immune modulation, and vascularization. The ability to monitor BMP pathway activation with this reporter system enables high-throughput screening of novel small molecules, biologics, and natural products for their effects on BMP signaling, with potential applications in drug discovery and toxicity testing.
This model is especially valuable for evaluating compounds that influence osteogenesis, tissue remodeling, fibrosis, and stem cell differentiation, as well as for identifying potential endocrine-disrupting chemicals or compounds that may affect BMP-related pathways. By quantifying the activity of the BMP/SMAD1/5/8 pathway, researchers can gain insights into how BMP-modulating drugs interact with other signaling cascades and assess their efficacy and safety. Such applications include:
-
High-throughput screening of small molecules, biologics, and natural products for BMP-modulatory effects.
-
Evaluating drug safety by assessing compound interactions with BMP pathways and the potential for off-target effects.
-
Toxicology studies to identify chemicals that may disrupt BMP signaling and lead to adverse effects, including in bone and tissue regeneration.
-
Identifying combination therapies by testing BMP pathway modulators in combination with other oncological or regenerative treatments.
Common inducers and inhibitors that can be used with this model:
-
BMP2, BMP4, BMP7, BMP9, or BMP10 to activate SMAD1/5/8 signaling.
-
Noggin, dorsomorphin, or LDN-193189 to inhibit BMP receptor activation.
-
TGF-β1 for cross-talk studies with other key pathways involved in toxicity, such as those involved in fibrosis or cancer.
Signosis offers the BMP/SMAD1/5/8 luciferase reporter cell line for fast, reproducible drug screening and toxicology studies, aiding researchers in the identification and validation of BMP-targeted therapies and potential safety concerns related to drug candidates.
